Prism Medico Faces Valuation Shift Amid Long-Term Growth Challenges and Underperformance

Prism Medico & Pharmacy, a microcap player in the Non-Banking Financial Company (NBFC) sector, has recently experienced an adjustment in its evaluation score. This revision reflects a shift in its valuation grade, now categorized as expensive.
Key financial metrics indicate a PE ratio of 12.99 and an EV to EBITDA ratio of 12.92, suggesting a notable valuation context. The company's Price to Book Value stands at 0.86, while its Return on Equity (ROE) is recorded at 4.64%. These figures highlight the company's current market position and profitability per unit of shareholders' funds.

Despite a positive financial performance in the latest quarter, Prism Medico has faced challenges in long-term growth, evidenced by a -0.20% CAGR in operating profits over the past five years. Additionally, the company's ability to service its debt appears constrained, with a poor EBIT to Interest ratio of -0.03.

Over the past year, the stock has underperformed the broader market, generating a return of -29.25%, compared to a -7.50% return from the BSE500 index.

For more insights on Prism Medico & Pharmacy's financial trends, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.